Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Исследование тепла (терапия антителами HER2 с Lutetium-177) (RAD202)

21 сентября 2026 г. обновлено: Radiopharm Theranostics, Ltd

Фаза 0/1 Исследование безопасности и переносимости 177LU-RAD202, радиоактивного антитела с лучетием-177 с рецептором 2 эпидермального фактора роста у пациентов с пациентами с усовершенствованными солидными опухолями

This is a first-in-human, Phase 0/1, open-label study of177Lu-RAD202 to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.

Обзор исследования

Статус

Рекрутинг

Вмешательство/лечение

Подробное описание

This is a first-in-human, Phase 0/1, open-label study of 177Lu-RAD202 consisting of a Screening Period, a Treatment Period with 177Lu-RAD202 and a Safety and Long-Term Follow-Up Period to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.

Screening Period: Screening period of up to 4 weeks Phase I (Treatment Period): 177Lu-RAD202 dose escalation

  • Treatment Period with each cycle lasting 6 weeks. Extension of the planned dose intervals are possible following discussion and agreement between the Sponsor and Investigator.
  • Participants may be treated with multiple cycles as long as they appear to derive clinical benefit as determined by the Investigator and provided adequate clinical safety and organ dosimetry data.
  • DLT observation period for 177Lu-RAD202 is 6 weeks following first injection of 177Lu-RAD202.
  • Should an alternative treatment schedule be explored, the DLT observation period for 177Lu-RAD202 at that dose level will be the proposed cycle duration.

Safety Follow-Up Period:

  • An End of Treatment Visit performed within 7 days of the last dose of 177Lu-RAD202
  • A Safety Follow-up Visit performed every 12 ± 2 weeks from the End of Treatment Visit

Тип исследования

Интервенционный

Регистрация (Оцененный)

30

Фаза

  • Ранняя фаза 1

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

Места учебы

    • New South Wales
      • Kingswood, New South Wales, Австралия, 2747
        • Рекрутинг
        • Nepean Hospital
        • Контакт:
      • Macquarie Park, New South Wales, Австралия, 2109
        • Рекрутинг
        • Macquarie University Hospital
        • Контакт:
      • Wollongong, New South Wales, Австралия, 2500
        • Рекрутинг
        • Wollongong Hospital
        • Контакт:
    • Victoria
      • Fitzroy, Victoria, Австралия, 3065
        • Рекрутинг
        • St Vincents Hospital, Melbourne
        • Контакт:
          • Melissa Moore, MD
          • Номер телефона: +61 3 9231 2211
          • Электронная почта: melissa.moore@svha.org.au
    • Western Australia
      • Murdoch, Western Australia, Австралия, 6150
        • Рекрутинг
        • GenesisCare Murdoch
        • Контакт:

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  1. Aged 18 years and older.

  2. Written, voluntary, informed consent of the participants must be obtained in compliance with institutional, regional, and federal guidelines.

  3. Participants with histologically or cytologically confirmed, HER2 positive or HER2-low, advanced solid tumours that are relapsed/refractory, locally advanced not amenable to curative-intent therapy, or metastatic, with documented disease progression during or after their most recent line of anti-cancer therapy. Participants must be refractory to or intolerant of standard of care therapy or have no standard of care therapy available that is likely to provide clinical benefit.

    Participant HER2 positivity is determined by local testing and is defined as a score of 3+ on immunohistochemical analysis IHC), or, defined as a score of 2+ on IHC and positive results on in situ hybridisation (ISH). HER2-low is defined as a score of 1+ on IHC analysis or a score of 2+ on IHC analysis with ISH negative. If the participant tumor's HER2 status is unknown, it may be determined in a pre-screening step whereby the participant is asked to provide written informed consent to have their tumor tissue undergo IHC testing as determined by a validated test (tumor tissue may be obtained from archived samples or from a freshly obtained biopsy).

  4. Must have at least 1 measurable target lesion according to RECIST version 1.1.

  5. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

  6. Participants must have a life expectancy of ≥4 months in the opinion of the Investigator.

  7. Women of childbearing potential (WOCBP) must have a negative serum beta-human chorionic gonadotropin (β-hCG) test and must not be breastfeeding. WOCBP are defined as those who are not surgically sterile or post-menopausal. Female participants will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.

  8. WOCBP must agree to use a highly effective method of contraception during the study and for 90 days after the last dose of 177Lu-RAD202. Acceptable methods of contraception are described in Section 12.3.3 of the Protocol.

  9. Male participants who are able to father a child must agree to avoid impregnating a partner and to adhere to a highly effective method of contraception during the study and for 90 days after the last dose of 177Lu-RAD202. All male participants must agree to not donate sperm during the study and at least 90 days after the last dose of 177Lu-RAD202, whichever occurs later. Acceptable methods of contraception are described in Section 12.3.3 of the Protocol.

  10. Participants with previously treated brain metastases are eligible to participate if:

    1. They are neurologically and radiologically stable (no evidence of progression by imaging; same imaging modality [magnetic resonance imaging (MRI) or computed tomography (CT) scan] must be used for each assessment),
    2. Do not require corticosteroids to treat associated neurological symptoms, and
    3. Participants have no history of leptomeningeal disease or spinal cord compression.
    4. Participants with active brain metastases untreated with brain-directed therapy such as radiotherapy, are not eligible.

Exclusion Criteria:

  1. Participants who have any other known, active malignancy, except for treated cervical intraepithelial neoplasia, or nonmelanoma skin cancer. Participants with a history of malignancies of low recurrence potential who have received curative-intent therapy may be approved on a case-by-case basis in discussion with the study Sponsor, if it is determined not to put the participant at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.

  2. Participants who have any medical condition that would, in the Investigator's judgment, prevent the participant's full participation in the clinical study due to safety concerns or compliance with clinical study procedures such as participants with severe claustrophobia who are unresponsive to oral anxiolytics, participants with low back pain who cannot lie comfortably on an imaging table, participants who are hyperactive or hyperkinetic such that they cannot tolerate lying still for multiple time-point imaging procedures, etc.

  3. Residual toxicity Grade ≥ 2 from previously administered therapy (except for alopecia). Patients with Grade 2 or higher toxicity due to prior treatment may be allowed on a case-by-case basis in discussion with study Sponsor provided it is deemed not to put the participant at a higher risk of treatment-related toxicity or interfere with the integrity of study data, e.g., participants with endocrinopathy on stable replacement therapy

  4. Inadequate organ functions as reflected in laboratory parameters:

    • Creatinine clearance or Body Surface Area (BSA) adjusted Estimated glomerular filtration rate (eGFR) (calculated using any clinically validated formula, preferably Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or measured) < 60 mL/min
    • Platelet count of < 80 x 109/L
    • Absolute neutrophil count (ANC) < 1.5 x 109/L
    • Haemoglobin < 9 g/dL
    • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 x upper limit of normal (ULN), or > 5 x ULN for participants with known liver metastases
    • Total bilirubin > 1.5 x ULN, except for participants with documented Gilbert's syndrome who are eligible if total bilirubin ≤ 3 x ULN
    • For participants not taking warfarin or other anticoagulants: international normalized ratio (INR) ≥ 1.5 or prothrombin time (PT) ≥ 1.5 × ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) ≥1.5 × ULN. Participants taking warfarin must be on a stable dose that results in a stable INR < 3.5. Among participants receiving other anticoagulant therapy, PT or aPTT must be within the intended therapeutic range of the anticoagulant.
  5. Significant cardiovascular disease including:

    • Unstable angina and/or myocardial infarction within 6 months prior to screening
    • New York Heart Association Class II or greater congestive heart failure
    • Clinically significant abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block)
    • QT interval corrected for heart rate using Fridericia's formula (QTcF) > 470 msec for females and QTcF > 450 msec for males on screening electrocardiogram (ECG) or congenital long QT syndrome
    • Uncontrolled hypertension
    • Known LVEF < 50%. (LVEF may be performed either by echocardiogram or other appropriate imaging modalities such as nuclear cardiac imaging (MUGA) or MRI).
  6. History of uncontrolled allergic reactions and/or have hypersensitivity to anti-HER2 monoclonal antibodies, kanamycin A or aminoglycoside therapies, or other excipients that may induce hypersensitivity

  7. Pregnant or lactating women

  8. Participants who are receiving any other investigational agents

  9. Received anti-cancer therapy, including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy or investigational device, within 28 days (or 5 half-lives for biologic/non-cytotoxic agents, whichever is shorter), prior to the first dose of 177Lu-RAD202.

  10. Has had or is scheduled to have major surgery ≤ 28 days prior to the first dose of 177Lu-RAD202. Surgical procedures not considered to put participants at higher risk of AEs and/or interfere with the integrity of study outcome may be allowed on a case-by-case basis in discussion with the Sponsor.

  11. Positive status for human immunodeficiency virus (HIV).

  12. Active or chronic hepatitis B or C. Chronic hepatitis B or hepatitis C with undetectable viral loads on stable suppression therapy may be allowed on a case-by-case basis in discussion with study Sponsor.

  13. Any medical condition which, in the opinion of the Investigator, places the participant at an unacceptably high risk for toxicities.

  14. Any uncontrolled intercurrent illness or clinically significant uncontrolled condition(s), including but not limited to active bacterial, fungal, or viral infections requiring systemic therapy.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Н/Д
  • Интервенционная модель: Одногрупповое задание
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: 177Lu-RAD202

Single-arm, open-label study of 177Lu-RAD202

177Lu-RAD202 administered at treatment doses

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Safety and tolerability of 177Lu-RAD202
Временное ограничение: 6 weeks

The properties, incidence, nature and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) per Common Terminology Criteria for Adverse Events (CTCAE) v5.0

6 weeks
Recommended dose(s) of 177Lu-RAD202 for future exploration
Временное ограничение: 6 weeks

Incidence of dose-limiting toxicities (DLTs) during the first 6 weeks following 177Lu-RAD202 injection cycle of treatment

6 weeks

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Preliminary antitumor activity of 177Lu-RAD202
Временное ограничение: Up to 30 weeks

Objective response rates (ORR) as assessed by RECIST v1.1

Up to 30 weeks
Time Activity Curves (TACs)
Временное ограничение: 72 hours

Percent of the injected activity vs time for selected organs and tumors

72 hours
Radiation dosimetry of 177Lu-RAD202
Временное ограничение: 72 hours

Absorbed radiation doses of 177Lu-RAD202tr in critical organs (e.g., kidneys, bone marrow)

72 hours
Pharmacokinetics of 177Lu-RAD202
Временное ограничение: 72 hours

Half-life of 177Lu-RAD202 in blood

72 hours
Biokinetics of 177Lu-RAD202
Временное ограничение: 72 hours

Time-integrated activity coefficients of 177Lu-RAD202 in organs and tumor lesions

72 hours

Другие показатели результатов

Мера результата
Мера Описание
Временное ограничение
To explore the use of SPECT/CT as a measure of preliminary anti-tumor activity of 177Lu-RAD202
Временное ограничение: Up to 30 weeks

Longitudinal assessments of quantitative tumor uptake of 177Lu-RAD202 using SPECT/CT

Up to 30 weeks
To study the effect of amino acid infusion on 177Lu-RAD202 radiation absorption
Временное ограничение: Up to 30 weeks

Absorbed radiation doses of 177Lu-RAD202 in critical organs (e.g. kidneys, bone marrow)

Up to 30 weeks
Level of agreement between 177Lu-RAD202 and standard of care imaging
Временное ограничение: Up to 30 weeks

Standard of care imaging may include but is not limited to 18F-FDG-PET, CT-scan and/or 99mTc-MDP-bone

Up to 30 weeks

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

12 февраля 2025 г.

Первичное завершение (Оцененный)

1 декабря 2027 г.

Завершение исследования (Оцененный)

1 декабря 2027 г.

Даты регистрации исследования

Первый отправленный

7 февраля 2025 г.

Впервые представлено, что соответствует критериям контроля качества

7 февраля 2025 г.

Первый опубликованный (Действительный)

13 февраля 2025 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

24 сентября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

21 сентября 2026 г.

Последняя проверка

1 сентября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Другие идентификационные номера исследования

  • RAD202.2022.0002

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

НЕТ

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

продукт, произведенный в США и экспортированный из США.

Да

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться